A formulary change for BCBSRI Commercial plans is being made in response to the current growth hormone shortage.
Several plans currently cover Norditropin and Genotropin as a preferred brand growth hormone. As of December 1st, 2023, Omnitrope was added to coverage as an additional preferred brand growth hormone option. Norditropin and Genotropin remain covered as a preferred brands. Manufacturers estimate that growth hormone shortages will continue through 2023.
If your patients have any questions about this change, here are some resources you can offer:
- Coverage or claims processing: they can call the number on their member ID card
- Norditropin: visit www.novocare.com
- Genotropin: visit www.genotropin.com/pfizer-bridge-program
- Omnitrope: visit https://www.omnitrope.com/omnisource